Ebi H - Search Results

1

SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition.

Lai X, Lui SKL, Lam HY, Adachi Y, Sim WJ, Vasilevski N, Armstrong NJ, Bridgeman SC, Main NM, Tan TZ, Tirnitz-Parker JEE, Thiery JP, Ebi H, Kumar AP, Eichhorn PJA. Lai X, et al. Among authors: ebi h. NPJ Precis Oncol. 2023 Dec 15;7(1):136. doi: 10.1038/s41698-023-00486-6. NPJ Precis Oncol. 2023. PMID: 38102334 Free PMC article.

2

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.

Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S. Kitai H, et al. Among authors: ebi h. Cancer Discov. 2016 Jul;6(7):754-69. doi: 10.1158/2159-8290.CD-15-1377. Epub 2016 May 6. Cancer Discov. 2016. PMID: 27154822 Free PMC article.

3

Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.

Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H. Adachi Y, et al. Among authors: ebi h. Carcinogenesis. 2017 Oct 26;38(11):1063-1072. doi: 10.1093/carcin/bgx091. Carcinogenesis. 2017. PMID: 28968756

4

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.

Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H. Kotani H, et al. Among authors: ebi h. Oncogene. 2018 Mar;37(13):1775-1787. doi: 10.1038/s41388-017-0035-9. Epub 2018 Jan 19. Oncogene. 2018. PMID: 29348459

5

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.

Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, Ebi H. Adachi Y, et al. Among authors: ebi h. Clin Cancer Res. 2020 Nov 15;26(22):5962-5973. doi: 10.1158/1078-0432.CCR-20-2077. Epub 2020 Sep 8. Clin Cancer Res. 2020. PMID: 32900796

6

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers.

Adachi Y, Kimura R, Hirade K, Ebi H. Adachi Y, et al. Among authors: ebi h. Cancers (Basel). 2021 Oct 11;13(20):5081. doi: 10.3390/cancers13205081. Cancers (Basel). 2021. PMID: 34680229 Free PMC article. Review.

7

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.

Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC. Cai J, et al. Among authors: ebi h. Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095. Cell Rep. 2022. PMID: 35905710 Free PMC article.

8

Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS.

Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N, Yamaguchi R, Ebi H. Adachi Y, et al. Among authors: ebi h. Nat Cancer. 2023 Jun;4(6):829-843. doi: 10.1038/s43018-023-00575-2. Epub 2023 Jun 5. Nat Cancer. 2023. PMID: 37277529

9

Precision Oncology and the Universal Health Coverage System in Japan.

Ebi H, Bando H. Ebi H, et al. JCO Precis Oncol. 2019 Dec 11;3:PO.19.00291. doi: 10.1200/PO.19.00291. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32923862 Free PMC article. Review.

10

Evaluation of ALK Fusion Newly Identified in Colon Cancer by a Comprehensive Genomic Analysis.

Hosono Y, Masuishi T, Mitani S, Yamaguchi R, Kato S, Yoshino T, Ebi H. Hosono Y, et al. Among authors: ebi h. JCO Precis Oncol. 2019 Dec;3:1-5. doi: 10.1200/PO.19.00268. JCO Precis Oncol. 2019. PMID: 35100727 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page